Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 4/20 | 0.39 |
| ▸ | MAOB | P27338 | 4/20 | 0.39 |
| ▸ | PRKCI | P41743 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | VHL | P40337 | 1/20 | 0.33 |
| ▸ | ELOC | Q15369 | 1/20 | 0.33 |
| ▸ | ELOB | Q15370 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.32 |
| ▸ | DAO | P14920 | 1/20 | 0.32 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.31 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30853821 | 0.88 | VHL (0.35) | MEN1KMT2AVHLELOCELOB | |
| SCHEMBL8250594 | 0.77 | PKM (0.35) | ALDH1A1TP53HPGDTDP1PKM | |
| SCHEMBL11302021 | 0.76 | MAOA (0.35) | MAOAMAOBPRKCICYP2A6MEN1 | |
| SCHEMBL2776823 | 0.76 | TSHR (0.47) | MAOAMAOBPRKCICYP2A6MEN1 | |
| SCHEMBL2432416 | 0.76 | MAOA (0.35) | MAOAMAOBPRKCICYP2A6MEN1 | |
| SCHEMBL15606074 | 0.76 | MAOA (0.35) | MAOAMAOBPRKCICYP2A6MEN1 | |
| SCHEMBL23142164 | 0.74 | CDC7 (0.44) | GRM5 | |
| SCHEMBL25796608 | 0.74 | CA2 (0.37) | MAOAMAOBPRKCICYP2A6MEN1 | |
| SCHEMBL3138935 | 0.72 | MEN1 (0.33) | MAOAMAOBPRKCICYP2A6MEN1 | |
| SCHEMBL2436103 | 0.72 | DAO (0.61) | MAOAMAOBPRKCIMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630521-B2 | Arylamides and methods of use thereof | GENZYME CORPORATION (US) | 2026-05-19 | — | — | US | disclosed |
| US-12157726-B2 | P-phenylenediamine derivative as potassium channel regulator and preparation method and medical application thereof | SHANGHAI ZHIMENG BIOPHARMA INC. | 2024-12-03 | — | — | US | disclosed |
| EP-3798220-B1 | P-PHENYLENEDIAMINE DERIVATIVE AS POTASSIUM CHANNEL REGULATOR AND PREPARATION METHOD AND MEDICAL APPLICATION THEREOF | SHANGHAI ZHIMENG BIOPHARMA INC (CN) | 2023-08-23 | — | — | EP | disclosed |
| EP-3798220-B1 | P-PHENYLENEDIAMINE DERIVATIVE AS POTASSIUM CHANNEL REGULATOR AND PREPARATION METHOD AND MEDICAL APPLICATION THEREOF | SHANGHAI ZHIMENG BIOPHARMA INC (CN) | 2023-08-23 | — | — | EP | disclosed |
| US-20230147360-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | GENZYME CORPORATION | 2023-05-11 | — | — | US | disclosed |
| US-20230147360-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | GENZYME CORPORATION | 2023-05-11 | — | — | US | disclosed |
| US-20230147360-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | GENZYME CORPORATION | 2023-05-11 | — | — | US | disclosed |
| US-20220227721-A1 | P-PHENYLENEDIAMINE DERIVATIVE AS POTASSIUM CHANNEL REGULATOR AND PREPARATION METHOD AND MEDICAL APPLICATION THEREOF | SHANGHAI ZHIMENG BIOPHARMA INC. (CN) | 2022-07-21 | — | — | US | disclosed |
| US-11365181-B2 | P-phenylenediamine derivative as potassium channel regulator and preparation method and medical application thereof | SHANGHAI ZHIMENG BIOPHARMA INC. (CN) | 2022-06-21 | — | — | US | disclosed |
| US-11365181-B2 | P-phenylenediamine derivative as potassium channel regulator and preparation method and medical application thereof | SHANGHAI ZHIMENG BIOPHARMA INC. (CN) | 2022-06-21 | — | — | US | disclosed |
| WO-2012022865-A3 | DEVICE FOR ASSEMBLING A VEHICLE ENGINE AUTOMATIC STOP-START ASSEMBLY ON THE BODY SHELL STRUCTURE OF THE VEHICLE AND ASSOCIATED METHOD OF ASSEMBLY | Peugeot Citroën Automobiles SA (FR) | 2012-05-10 | — | — | WO | disclosed |
| US-20120088751-A1 | PHARMACEUTICAL COMPOUNDS | NEUROSCIENCZE PHARMANESS S.C. A R.L. (IT) | 2012-04-12 | — | — | US | disclosed |
| US-8106218-B2 | Pharmaceutical compounds | NEUROSCIENZE PHARMANESS S.C. A R.L. (IT) | 2012-01-31 | — | — | US | disclosed |
| EP-1602658-B1 | Tricyclic pyrazole derivatives as cannabinoid receptor antagonists | NEUROSCIENZE PHARMANESS S C A R L (IT) | 2011-12-07 | — | — | EP | disclosed |
| EP-2230243-A1 | Pharmaceutical compounds | Neuroscienze Pharmaness S.C. A R.L. (IT) | 2010-09-22 | — | — | EP | disclosed |
| US-20100215759-A1 | PHARMACEUTICAL COMPOUNDS | NEUROSCIENZE PHARMANESS S.C.A.R.L. (IT) | 2010-08-26 | — | — | US | disclosed |
| US-20090081123-A1 | PHARMACEUTICAL COMPOUNDS | CENERX BIOPHARMA (US) | 2009-03-26 | — | — | US | disclosed |
| US-7485730-B2 | Pharmaceutical compounds | NEUROSCIENZE PHARMANESS S.C. A R.L. (IT) | 2009-02-03 | — | — | US | disclosed |
| US-20050282798-A1 | Tricyclic pyrazole derivatives having affinity for cannabinoidergic CB1 and/or CB2 receptors; less side effects on the central nervous system; N-piperidinyl-7-chloro-1-(2',4'-dichlorophenyl)-4,5-dihydro-1H-thieno[2,3-g]indazol-3-carboxamide; immune disorders, osteoporosis, renal ischemia, inflammation | NEUROSCIENZE PHARMANESS S.C. A R.L. (IT) | 2005-12-22 | — | — | US | disclosed |
| EP-1602658-A1 | Tricyclic pyrazole derivatives as cannabinoid receptor antagonists | Neuroscienze Oharmaness S.c.a.r.l. (IT) | 2005-12-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12157726-B2 | P-phenylenediamine derivative as potassium channel regulator and preparation method and medical application thereof | KCNJ2, KCNN2, KCNH2 | MAOA 1302/4885MAOB 1320/4885PRKCI 966/4885 |
| US-20050282798-A1 | Tricyclic pyrazole derivatives having affinity for cannabinoidergic CB1 and/or CB2 receptors; less side effects on the central nervous system; N-piperidinyl-7-chloro-1-(2',4'-dichlorophenyl)-4,5-dihydro-1H-thieno[2,3-g]indazol-3-carboxamide; immune disorders, osteoporosis, renal ischemia, inflammation | CNR2, CNR1, GPR55 | MAOA 3284/4885MAOB 2340/4885PRKCI 641/4885 |
| US-20230147360-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | CFTR, AADAC, ARSA | MAOA 1786/4885MAOB 1413/4885PRKCI 2276/4885 |
| US-20220227721-A1 | P-PHENYLENEDIAMINE DERIVATIVE AS POTASSIUM CHANNEL REGULATOR AND PREPARATION METHOD AND MEDICAL APPLICATION THEREOF | KCNJ2, KCNN2, KCNH2 | MAOA 1302/4885MAOB 1320/4885PRKCI 966/4885 |
| US-11365181-B2 | P-phenylenediamine derivative as potassium channel regulator and preparation method and medical application thereof | KCNJ2, KCNN2, KCNH2 | MAOA 1299/4885MAOB 1329/4885PRKCI 948/4885 |
| US-12630521-B2 | Arylamides and methods of use thereof | CFTR, CLIC1, CLCN2 | MAOA 2954/4885MAOB 2770/4885PRKCI 1214/4885 |
| US-20100215759-A1 | PHARMACEUTICAL COMPOUNDS | CNR2, CNR1, OPRK1 | MAOA 826/4885MAOB 329/4885PRKCI 1911/4885 |
| US-20120088751-A1 | PHARMACEUTICAL COMPOUNDS | CNR2, CNR1, OPRK1 | MAOA 683/4885MAOB 313/4885PRKCI 1263/4885 |
| US-20090081123-A1 | PHARMACEUTICAL COMPOUNDS | CNR2, CNR1, OPRK1 | MAOA 628/4885MAOB 294/4885PRKCI 1298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.